I agree, violently. Protecting the researching company&#x27;s incentives is hugely important. Otherwise we&#x27;re getting the current crop of drugs at the expense of future drugs.<p>Eminent domain requires &quot;just compensation&quot; that courts interpret as fair market value. Since the company that created the drug was recently acquired there&#x27;s a really easy number to put on it.